{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:04:41Z","timestamp":1772114681229,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10549-020-05617-2","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T16:03:57Z","timestamp":1585929837000},"page":"199-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4\/6 inhibitors"],"prefix":"10.1007","volume":"181","author":[{"given":"Maria Alice","family":"Franzoi","sequence":"first","affiliation":[]},{"given":"Caroline","family":"Vandeputte","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Eiger","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Caparica","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"given":"Claudia","family":"De Angelis","sequence":"additional","affiliation":[]},{"given":"Alain","family":"Hendlisz","sequence":"additional","affiliation":[]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"5617_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.critrevonc.2018.06.011","volume":"129","author":"I Trestini","year":"2018","unstructured":"Trestini I, Carbognin L, Monteverdi S et al (2018) Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Crit Rev Oncol Hematol 129:54\u201366","journal-title":"Crit Rev Oncol Hematol"},{"key":"5617_CR2","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1200\/JCO.2014.58.4680","volume":"32","author":"JA Ligibel","year":"2014","unstructured":"Ligibel JA, Alfano CM, Courneya KS et al (2014) American Society of Clinical Oncology Position Statement on Obesity and Cancer. J Clin Oncol 32:3568\u20133574","journal-title":"J Clin Oncol"},{"key":"5617_CR3","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1016\/j.clbc.2018.04.010","volume":"18","author":"WK Cho","year":"2018","unstructured":"Cho WK, Choi DH, Park W et al (2018) Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer 18:e1141\u2013e1147","journal-title":"Clinical Breast Cancer"},{"key":"5617_CR4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan DSM, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901\u20131914","journal-title":"Ann Oncol"},{"key":"5617_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/annonc\/mdx152","volume":"28","author":"R Yerushalmi","year":"2017","unstructured":"Yerushalmi R, Dong B, Chapman JW et al (2017) Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28:1560\u20131568","journal-title":"Ann Oncol"},{"key":"5617_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.breast.2018.05.005","volume":"40","author":"L Zewenghiel","year":"2018","unstructured":"Zewenghiel L, Lindman H, Valachis A (2018) Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study. The Breast 40:136\u2013140","journal-title":"The Breast"},{"key":"5617_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12885-019-5319-8","volume":"19","author":"N Charette","year":"2019","unstructured":"Charette N, Vandeputte C, Ameye L et al (2019) Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. BMC Cancer 19:134","journal-title":"BMC Cancer"},{"key":"5617_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1055-9965.EPI-15-1336","volume":"26","author":"H Greenlee","year":"2017","unstructured":"Greenlee H, Unger JM, LeBlanc M et al (2017) Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev 26:21\u201329","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5617_CR9","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-17-3287","volume":"78","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Feliciano EMC, Kroenke CH (2018) The Importance of Body Composition in Explaining the Overweight Paradox in Cancer\u2014Counterpoint. Cancer Res 78:1906\u20131912","journal-title":"Cancer Res"},{"key":"5617_CR10","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/jcsm.12379","volume":"9","author":"JC Brown","year":"2018","unstructured":"Brown JC, Cespedes Feliciano EM, Caan BJ (2018) The evolution of body composition in oncology\u2014epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle 9:1200\u20131208","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"5617_CR11","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35:3638\u20133646","journal-title":"J Clin Oncol"},{"key":"5617_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541\u20131547","journal-title":"Ann Oncol"},{"key":"5617_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V et al (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174:719\u2013729","journal-title":"Breast Cancer Res Treat"},{"key":"5617_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/emmm.201000089","volume":"2","author":"V Aguilar","year":"2010","unstructured":"Aguilar V, Fajas L (2010) Cycling through metabolism. EMBO Mol Med 2:338\u2013348","journal-title":"EMBO Mol Med"},{"key":"5617_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1172\/JCI81480","volume":"126","author":"S Lagarrigue","year":"2015","unstructured":"Lagarrigue S, Lopez-Mejia IC, Denechaud P-D et al (2015) CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation 126:335\u2013348","journal-title":"Journal of Clinical Investigation"},{"key":"5617_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2013.00004","volume":"3","author":"L Fajas","year":"2013","unstructured":"Fajas L (2013) Re-thinking cell cycle regulators: the cross-talk with metabolism. Frontiers in Oncology 3:1\u20136","journal-title":"Frontiers in Oncology"},{"key":"5617_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41467-018-03451-1","volume":"9","author":"X Hou","year":"2018","unstructured":"Hou X, Zhang Y, Li W et al (2018) CDK6 inhibits white to beige fat transition by suppressing RUNX1. Nature Communications 9:1023","journal-title":"Nature Communications"},{"key":"5617_CR18","doi-asserted-by":"publisher","first-page":"e123000","DOI":"10.1172\/jci.insight.123000","volume":"3","author":"NJ Iqbal","year":"2018","unstructured":"Iqbal NJ, Lu Z, Liu SM et al (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI Insight 3:e123000","journal-title":"JCI Insight"},{"key":"5617_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.clnu.2011.12.011","volume":"31","author":"R Thibault","year":"2012","unstructured":"Thibault R, Genton L, Pichard C (2012) Body composition: why, when and for who? Clin Nutr 31:435\u2013447","journal-title":"Clin Nutr"},{"key":"5617_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997\u20131006","journal-title":"Appl Physiol Nutr Metab"},{"key":"5617_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jamaoncol.2018.0137","volume":"4","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol 4:798\u2013804","journal-title":"JAMA Oncol"},{"key":"5617_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-017-4574-0","volume":"168","author":"HN Rier","year":"2018","unstructured":"Rier HN, Jager A, Sleijfer S et al (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95\u2013105","journal-title":"Breast Cancer Res Treat"},{"key":"5617_CR23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1634\/theoncologist.2016-0066","volume":"21","author":"HN Rier","year":"2016","unstructured":"Rier HN, Jager A, Sleijfer S et al (2016) The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist 21:1396\u20131409","journal-title":"Oncologist"},{"key":"5617_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","volume":"6","author":"C Yip","year":"2015","unstructured":"Yip C, Dinkel C, Mahajan A et al (2015) Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 6:489\u2013497","journal-title":"Insights Imaging"},{"key":"5617_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.09.001","volume":"54","author":"SMR Kazemi-Bajestani","year":"2016","unstructured":"Kazemi-Bajestani SMR, Mazurak VC, Baracos V (2016) Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 54:2\u201310","journal-title":"Semin Cell Dev Biol"},{"key":"5617_CR26","doi-asserted-by":"publisher","first-page":"O256","DOI":"10.1111\/codi.13067","volume":"17","author":"D-D Huang","year":"2015","unstructured":"Huang D-D, Wang S-L, Zhuang C-L et al (2015) Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis 17:O256\u2013264","journal-title":"Colorectal Dis"},{"key":"5617_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/SLA.0000000000001113","volume":"263","author":"G Malietzis","year":"2016","unstructured":"Malietzis G, Johns N, Al-Hassi HO et al (2016) Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal Cancer. Ann Surg 263:320\u2013325","journal-title":"Ann Surg"},{"key":"5617_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CMM Prado","year":"2008","unstructured":"Prado CMM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629\u2013635","journal-title":"Lancet Oncol"},{"key":"5617_CR29","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CMM Prado","year":"2007","unstructured":"Prado CMM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264\u20133268","journal-title":"Clin Cancer Res"},{"key":"5617_CR30","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.ctarc.2019.100154","volume":"21","author":"F Rossi","year":"2019","unstructured":"Rossi F, Valdora F, Bignotti B et al (2019) Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review. Cancer Treat Res Commun 21:100154","journal-title":"Cancer Treat Res Commun"},{"key":"5617_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11764-012-0234-x","volume":"6","author":"A Villase\u00f1or","year":"2012","unstructured":"Villase\u00f1or A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6:398\u2013406","journal-title":"J Cancer Surviv"},{"key":"5617_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.breast.2016.10.014","volume":"31","author":"HN Rier","year":"2017","unstructured":"Rier HN, Jager A, Sleijfer S et al (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9\u201315","journal-title":"Breast"},{"key":"5617_CR33","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CMM Prado","year":"2009","unstructured":"Prado CMM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920\u20132926","journal-title":"Clin Cancer Res"},{"key":"5617_CR34","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.5301\/tj.5000515","volume":"102","author":"A Gevorgyan","year":"2016","unstructured":"Gevorgyan A, Bregni G, Galli G et al (2016) Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. Tumori 102:e11\u201314","journal-title":"Tumori"},{"key":"5617_CR35","doi-asserted-by":"publisher","first-page":"69025","DOI":"10.18632\/oncotarget.16982","volume":"8","author":"L Pizzuti","year":"2017","unstructured":"Pizzuti L, Natoli C, Gamucci T et al (2017) Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Oncotarget 8:69025\u201369037","journal-title":"Oncotarget"},{"key":"5617_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-014-3091-7","volume":"147","author":"SJ Ioannides","year":"2014","unstructured":"Ioannides SJ, Barlow PL, Elwood JM et al (2014) Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat 147:237\u2013248","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"5617_CR37","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.ijo.0802906","volume":"29","author":"S Miard","year":"2005","unstructured":"Miard S, Fajas L (2005) Atypical transcriptional regulators and cofactors of PPARgamma. Int J Obes (Lond) 29(Suppl 1):S10\u201312","journal-title":"Int J Obes (Lond)"},{"key":"5617_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cmet.2005.09.003","volume":"2","author":"A Abella","year":"2005","unstructured":"Abella A, Dubus P, Malumbres M et al (2005) Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab 2:239\u2013249","journal-title":"Cell Metab"},{"key":"5617_CR39","unstructured":"Fielding RA, Vellas B, Evans WJ, et al: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249\u2013256, 2011"},{"key":"5617_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16\u201331","journal-title":"Age Ageing"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-05617-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T23:23:00Z","timestamp":1617405780000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-05617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5617"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05617-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MAF, CV, AH and CDA: none. DE: Funding for his ESMO fellowship: Novartis. RC: speaker honoraria from Boehringer Ingelheim, AstraZeneca and Janssen, travel grants from AstraZeneca and Pfizer. MB: travel grant and speaker honoraria from Roche\/GNE. AA: Advisory role, speaker fees and research funding for his institute from: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma. M.P.: Board Member (Scientific Board): Oncolytics, Radius; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics; Research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon; Speakers bureau\/stock ownership: none. EA: honoraria and advisory board: Roche\/GNE, Novartis, Seatle Genetics; travel grants: Roche\/GNE, GSK\/Novartis; co-principal investigator of the LORELEI trial (NCT02273973). Research grant for his institute: Roche\/GNE, Astra-Zeneca, Novartis,\u00a0and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This study was approved by an internal ethics committee (EC3048), and informed consent was not required as patient\u2019s information was retrieved from retrospective review of medical records only. The identity of the patients was kept always anonymously.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}